<DOC>
	<DOCNO>NCT01582399</DOCNO>
	<brief_summary>The objective study ass level ASKP1240 blood single dose give intravenously ( IV ) subcutaneous ( SC ) injection . The study determine drug behaves inside body eliminate body look pharmacokinetics ASP1240 . In addition , study determine effect ASKP1240 body look pharmacodynamics ( PD ) safety tolerability ASKP1240 give IV SC injection .</brief_summary>
	<brief_title>Bioavailability ASKP1240 Healthy Subjects After Intravenous Subcutaneous Administration ASKP1240</brief_title>
	<detailed_description />
	<criteria>The subject weigh least 50 kg , body mass index ( BMI ) 18 32 kg/m2 , inclusive The female subject must ) least two year postmenopausal ( define least 2 year without menses ) Screening confirmatory follicle stimulate hormone ( FSH ) level &gt; 40 U/L Screening ) b ) surgically sterile ( documentation provide healthcare professional ) pregnant lactate Screening Day 1. c ) If child bear potential , subject require use adequate contraception consist two form birth control ( one must barrier method ) end study 90 day final study drug administration , whichever long The male subject agree sexual abstinence , surgically sterile ( documentation provide healthcare professional ) , use medically acceptable method ( e.g . spermicide diaphragm , spermicide condom ) prevent pregnancy agree continue use method end study Male subject agree sperm donation end study 90 day conclusion study drug administration , whichever long The subject history evidence clinically significant ( determined Investigator ) cardiovascular , endocrine , ophthalmologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary ( include asthma emphysema ) , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy ( exclude nonmelanoma skin cancer ) The subject history severe allergic anaphylactic reaction The subject history consume 14 unit alcoholic beverage ( one unit 12 ounce beer , 4 ounce wine 1 ounce spirit ) per week average within 6 month prior Screening history alcoholism drug/chemical/substance abuse within past 2 year prior Screening subject test positive Screening Day 1 alcohol drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) The subject has/had symptomatic , viral , bacterial fungal ( noncutaneous ) infection within 1 week prior clinic check Day 1 The subject history thromboembolic vascular disease especially deep vein thrombosis pulmonary embolism The subject use tobaccocontaining product , nicotine nicotinecontaining product past 6 month prior Screening The subject supine mean systolic blood pressure &lt; 90 &gt; 160 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg , mean heart rate &gt; 100 beat per minute ( bpm ) , either Screening Day 1 ( measurement take triplicate subject rest supine position minimum 5 minute ) The subject know positive human immunodeficiency virus ( HIV ) antibody The subject positive test hepatitis C virus ( HCV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody Screening The subject follow Screening Day 1 : 1 . White blood cell count ( WBC ) &lt; 3.5 ( 109/L ) &gt; upper limit normal 2 . Absolute neutrophil count ( ANC ) &lt; 1.5 ( 109/L ) &gt; upper limit normal 3 . Platelet count ( PLT ) outside normal limit 4 . Serum creatinine , total bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; upper limit normal 5 . Creatine phosphokinase ( CPK ) &gt; 2x time upper limit normal 6. International normalize ratio ( INR ) &gt; upper limit normal 7 . Remaining laboratory test outside normal limit consider investigator clinically significant regard remain perprotocol laboratory test The subject receive vaccine within 60 day prior Day 1 The subject receive systemic immunosuppressant agent ( e.g. , methotrexate ) within 6 month prior Day 1 The subject receive systemic steroid within 2 month prior Day 1 The subject receive antibody therapeutic biologic product within 6 month prior Day 1 The subject use prescription nonprescription medication ( exclude acetaminophen [ 2 g/day maximum ] , stable hormone replacement therapy [ HRT ] , and/or nasal steroids/steroid inhaler ) , complementary alternative medicine ( CAM ) within 14 day 5 half life ( whichever longer ) prior Day 1 The subject positive TB skin test , Quantiferon Gold test TSPOT testÂ® Screening The subject participate previous ASKP1240 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>CD40 receptor occupancy</keyword>
	<keyword>Co-stimulation blockade</keyword>
	<keyword>CD40 antigen</keyword>
	<keyword>Anti-CD40</keyword>
	<keyword>ASKP1240</keyword>
</DOC>